Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 7, 2015, Pages 2707-2712

  Cingeetham, Anuradha ^a   Vuree, Sugunakar ^a   Jiwatani, Sangeeta ^b   Kagita, Sailaja ^b   Dunna, Nageswara Rao ^d   Meka, Phanni Bhushann ^a   Gorre, Manjula ^a   Annamaneni, Sandhya ^a   Digumarti, Raghunadharao ^b   Sinha, Sudha ^c   Satti, Vishnupriya ^a  

^a OSMANIA UNIVERSITY   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^c Institute of Oncology and Regional Cancer Centre   (India)

^d SASTRA UNIVERSITY   (India)

Author keywords

AML; Complete remission; Disease free survival; MDM2; RT PCR; Tetra primer (ARMS) PCR

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; PROTEIN P53; TP53 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CASE CONTROL STUDY; CELL TRANSFORMATION; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84928600939     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.7.2707     Document Type: Article

References (21)

1. Barak Y, Gottlieb E, Juven-Gershon T, Oren M (1994). Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev, 8, 1739-49.
2. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
3. Boyd MT, Vlatkovic N, Haines DS (2000). A novel cellular protein (MTBP) binds to MDM2 and Induces a G1 arrest that is suppressed by MDM2. J Bio Chern, 275, 31883-90.
4. Brown CY, Mize GJ, Pineda M, George DL, Morris DR (1999). Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene, 18, 5631-7.
5. Cheng TH, Cohen SN (2007). Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol Cell Biol, 27, 111-9.
6. Ebid GT, Sedhom IA, El-Gammal MM, Moneer MM (2012). MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Asian Pac J Cancer Prev, 13, 4315-20.
7. Ellis NA, Huo D, Yildiz O, et al (2008). MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 112, 741-9.
8. Hong Y, Miao X, Zhang X, et al (2005). The Role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res, 65, 9582-7.
9. Lahiri DK and Nurnberger JI (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res, 19, 5444.
10. Michael D, Oren M (2002). The p53 and Mdm2 families in cancer. Curr Opin Genet Dev, 12, 53-9.
11. Montes de Oca Luna R, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, et al (1996). The organization and expression of the mdm2 gene. Genomics, 33, 352-7.
12. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-3.
13. Phillips CL, Gerbing R, Alonzo T et al (2010). MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the children's Oncology Group. Pediatr Blood Cancer, 55, 248-53.
14. Rayburn E, Zhang R, He J, Wang H (2005). MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets, 5, 27-41.
15. Wan Y, Wu W, Yin Z, Guan P, Zhou B (2011). MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11, 208.
16. Xiao M, Zhang L, Zhu X, et al (2010). Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer, 10, 147.
17. Xiong X, Wang M Wang L, et al (2009). Risk of MDM2SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res, 33, 1454-8.
18. Wan Y, Wu W, Yin Z, Guan P, Zhou B (2011). MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis. BMC Cancer. 11, 208.
19. Yan YL, Han F, Tan WM, Wu CP, Qin X (2014). Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 6767-72.
20. Ye Y, Li X, Yang J, et al (2013). MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci, 104, 590-98.
21. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M (1995). A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res, 23, 2584-92.